Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats neuromyelitis optica spectrum disorder (NMOSD). Sold as Enspryng. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Satralizumab (sold as Enspryng), first approved Aug 14, 2020, with 1 new use approved and 0 published complete response letters.
First approved in Japan 2 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Enspryng, new ingredientA drug with a new active ingredient indicated for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). · Chugai Pharmaceutical Co., Ltd. · Jun 29, 2020 · Review report
Clinical Trials
11 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
